Pharmafile Logo
Pharmafocus logo
Advanced Search

Afinitor

Showing 6 posts of 36 posts found.

Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

News

FDA approves Novartis’ Afinitor

November 1, 2010
Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis

Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …

News

NICE poised to reject Novartis’ Afinitor

July 8, 2010
Sales and Marketing Afinitor, NICE, Novartis

Novartis’ kidney cancer drug Afinitor does not offer enough benefit to patients to justify its cost, according to draft guidance …

News

Triple approval for Novartis in Japan

January 20, 2010
Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension

Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …

News

Afinitor approved in EU

August 6, 2009
Research and Development, Sales and Marketing Afinitor, Cancer, Europe, Novartis

Novartis’ new kidney cancer drug Afinitor (everolimus) has been approved in the EU for use when products such as Sutent …

News

Strong prospects for Novartis cancer drug, say analysts

April 24, 2009
Research and Development, Sales and Marketing Afinitor, Novartis

The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025